Control of foodstuffs and medicines USA (FDA) approved the production of a new generic drug Vitrakvi against cancer, was developed by company Loxo Oncology, in collaboration with the company Bayer. The peculiarity of the drug is that it is designed to combat mutations in cancer tumors at the genetic level. The technique can be used to treat any type of cancer — only the type of genetic distortion is important, not the location of the cancer. This publication reports Business Insider.
Medicine is expensive. A year’s supply of Vitrakvi 393 will cost thousands of dollars. Bayer said in a statement that every year 2500-3000 people are diagnosed with genetic mutations that lead to the development of cancer. It is also reported that for children the drug will be produced in liquid form, and its price for the annual volume of this case will be reduced to 132 000 dollars a year. Bayer also reports that it is going to offer financial assistance to those patients who will not be able to pay the full cost of the medicine. In this case, the price will be significantly reduced for them – the cost of a monthly supply of Vitrakvi will be $ 20, which is quite feasible for most patients.
“Today’s approval means another important step in the fight against various types of cancer, taking into account their tumor genetics, and not just on the basis of their local origin in the body,” — reported on the website of the us Food and drug administration.
In 2017, Loxo Oncology signed an agreement with the pharmaceutical giant Bayer for $ 1.5 billion to develop and bring two Loxo drugs, including Vitrakvi, to the commercial market. During the tests this drug called paratrechina (larotrectinib LOXO-101).
The use of funds aimed at certain genetic mutations, represents a new approach in the treatment of cancer. Most pharmaceutical companies develop drugs that only treat a particular type of cancer, such as lung cancer or melanoma. In this case, it is necessary to obtain the approval of regulatory authorities each time to check the impact of these drugs on other cancers.
Deciphering the genetic picture of tumors is often used in modern medicine. However, this approach attracted much attention only in 2013, when scientists discovered that endometrial cancer has a similar genetic pattern with ovarian and breast cancer.
In may 2017, the FDA approved the first drug to treat genetic mutations, paving the way for the development of similar drugs by other manufacturers, including Loxo. The new drug Loxo Oncology affects a certain type of mutation-TRK-merged gene. It leads to the development of various types of cancer: sarcoma, thyroid cancer, non-small cell lung cancer and other types.
Human trials of the drug have shown positive results. At the last meeting of the European society of medical Oncology, Loxo Oncology said that among 109 patients treated with This drug in the framework of studies, 81 percent had a General positive trend in the treatment – the size of cancer tumors decreased. At the same time, in 17 percent of cases, patients had a complete positive response – the cancer completely retreated from their body.